# DaVita Inc. (DVA) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Health Care Equipment & Supplies. Price $183.99, market value $11.7 billion.

## Valuation
- **P/E (trailing): 15.6×** (5-yr avg 13.0×, 3-yr avg 13.2×). DaVita Inc. trades at 15.6× trailing earnings, close to its own five-year average of 13.0×. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 10.7×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 0.8×**. Each dollar of revenue is priced at 0.8×, a low multiple typical of thin-margin businesses or out-of-favour stocks.
- **EV / EBITDA: 7.5×**. Enterprise value is 7.5× operating earnings before depreciation, the multiple that ignores how the company is financed; below 8× is inexpensive for most sectors.
- **Free-cash-flow yield: 13.7%** (5-yr avg 13.1%). Free cash flow equals 13.7% of the market value, in line with its five-year average of 13.1%. Above 5% is generally attractive.
- **Earnings yield: 6.4%**. The inverse of the P/E: 6.4% of the price is earned each year.

## Profitability
- **Operating margin: 15.2%**. 15.2% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: 5.5%**. 5.5% of each dollar of sales reaches the bottom line.
- **Return on equity: -114.7%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: 18.8%**. Return on all capital, debt included, is 18.8%: comfortably above what that capital costs.
- **Return on assets: 4.8%**. Each dollar of assets produces 4.8% of profit.

## Growth
- **Revenue growth (1 yr): 6.5%** (3-yr 5.5%/yr, 5-yr 3.4%/yr). Revenue grew 6.5% over the last year, against 3.4% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): -8.3%** (3-yr 18.9%/yr, 5-yr 9.3%/yr). Earnings per share fell 8.3%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): 10.9%/yr**. Free cash flow has compounded at 10.9% a year over three years, lagging earnings: check whether profits are turning into cash.

## Financial health
- **Net debt / EBITDA: 3.4×**. It would take 3.4 years of operating earnings to repay net borrowings, above the 3× level most lenders treat as comfortable.
- **Current ratio: 1.29** (quick 1.29). Current assets cover the next year's liabilities 1.29 times.
- **Altman Z-score: 1.61**. A Z-score of 1.61 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. DaVita Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (7 analysts). 7 analysts cover DaVita Inc.; the consensus is buy, with an average price target of $218.43 (+19% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 35.7%** (YTD 61.9%, 3-mo -4.3%). The shares are up 35.7% over twelve months including dividends.
- **From 52-week high: -25.7%** (82.2% above the low). Trading 26% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 44**. An RSI of 44 is neutral.
- **Beta (1 yr): 0.02** (volatility 45%). Beta of 0.02 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=DVA · Page: https://foliofundamentals.com/stocks/dva

Not investment advice.